Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE

Sastry, Jairam, Kellie, Stewart J.·2005·Pediatric Hematology and Oncology

Abstract

Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors. Amifostine, a broad-spectrum cytoprotector of normal tissues, has been approved by U.S. Food and Drug Administration for use in patients receiving cisplatin. Such administration of amifostine has been reported to reduce cisplatin-related toxicities in some studies, but not all. The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/08880010590964381

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 258

Metadata

Authors
Sastry, J., & Kellie, S. J.
Venue
Pediatric Hematology and Oncology
Published
2005-01
Volume
22
Issue
5
Pages
441-445
ISSN
  • 0888-0018 (ISSN-L)
  • 1521-0669
OpenAlex
W2059068055
Cited by
258
References
7
FWCI
2.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE. https://app.cochat.ai/papers/10.1080/08880010590964381
The paper
Sastry, J., & Kellie, S. J. (2005). SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE. Pediatric Hematology and Oncology. https://doi.org/10.1080/08880010590964381

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.